A phase II trial of a multi-agent oral antiangiogenic (metronomic) regimen in children with recurrent or progressive cancer.

Autor: Robison NJ; Department of Pediatric Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts; Division of Pediatric Hematology-Oncology, Department of Pediatrics, Boston Children's Hospital, Boston, Massachusetts., Campigotto F, Chi SN, Manley PE, Turner CD, Zimmerman MA, Chordas CA, Werger AM, Allen JC, Goldman S, Rubin JB, Isakoff MS, Pan WJ, Khatib ZA, Comito MA, Bendel AE, Pietrantonio JB, Kondrat L, Hubbs SM, Neuberg DS, Kieran MW

Publikováno v: Pediatric blood & cancer [Pediatr Blood Cancer] 2014 Apr; Vol. 61 (4), pp. 636-42. Date of Electronic Publication: 2013 Oct 04.